Recently, Livzon Group Livzon Pharmaceutical Factory a wholly-owned subsidiary of Livzon Pharmaceutical Group Inc. (the Company) received the Approval Notice for Supplementary Application for Drug approved and issued by the National Medical Products Administration, stating that Valsartan Capsules manufactured by Livzon Pharmaceutical Factory passed the consistency evaluation on quality and efficacy for generics, details of which are announced as follows: Name of the Drug: Valsartan Capsules; Dosage Form: Capsules. Strength: 80 mg. Registration Classification: chemical drug. Drug Registration Standard Number: YBH06082022. Marketing Authorization Holder: Livzon Group Livzon Pharmaceutical Factory. Acceptance Number: CYHB2150701. Approval conclusion: pursuant to the requirements of Drug Administration Law of the People's Republic of China, Opinions of the State Council on Reform of the System of Evaluation, Review and
Approval of Drugs and Medical Devices (Guo Fa [2015] No. 44) and Announcement on Matters Related to Consistency Evaluation on Quality and Efficacy for Generics (No. 100 of 2017), upon review, this drug passed the consistency evaluation on quality and efficacy for generics.